{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,26]],"date-time":"2026-10-26T21:22:59Z","timestamp":1793049779914,"version":"4.5.0"},"reference-count":24,"publisher":"Springer Science and Business Media LLC","issue":"1","license":[{"start":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T00:00:00Z","timestamp":1777248000000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"},{"start":{"date-parts":[[2026,6,15]],"date-time":"2026-06-15T00:00:00Z","timestamp":1781481600000},"content-version":"vor","delay-in-days":49,"URL":"https:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0"}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["J Transl Med"],"DOI":"10.1186\/s12967-026-08178-y","type":"journal-article","created":{"date-parts":[[2026,4,27]],"date-time":"2026-04-27T15:23:55Z","timestamp":1777303435000},"update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":2,"title":["LAG3 as a potential biomarker in breast cancer: integrated tissue and peripheral blood analysis reveals clinical and pathomic insights in triple-negative disease"],"prefix":"10.1186","volume":"24","author":[{"given":"A.","family":"Balestrieri","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Brancato","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"S.","family":"Scippa","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"R.","family":"Cirella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"G.","family":"Mossetti","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"D\u2019aiuto","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"M.","family":"Salvatore","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"A.","family":"Soricelli","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"V.","family":"Ciaramella","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"297","published-online":{"date-parts":[[2026,4,27]]},"reference":[{"issue":"4","key":"8178_CR1","doi-asserted-by":"publisher","first-page":"460","DOI":"10.1016\/j.annonc.2025.01.014","volume":"36","author":"C Santucci","year":"2025","unstructured":"Santucci C, Mignozzi S, Levi F, Malvezzi M, Boffetta P, Negri E, et al. European cancer mortality predictions for the year 2025 with focus on breast cancer. Ann Oncol. 2025;36(4):460\u201368. https:\/\/doi.org\/10.1016\/j.annonc.2025.01.014.","journal-title":"Ann Oncol"},{"key":"8178_CR2","doi-asserted-by":"publisher","first-page":"18","DOI":"10.3389\/fpubh.2019.00018","volume":"7","author":"F Hossain","year":"2019","unstructured":"Hossain F, Danos D, Prakash O, Gilliland A, Ferguson TF, Simonsen N, et al. Neighborhood social determinants of triple negative breast cancer. Front Public Health. 2019;7:18. https:\/\/doi.org\/10.3389\/fpubh.2019.00018.","journal-title":"Front Public Health"},{"key":"8178_CR3","doi-asserted-by":"publisher","first-page":"311","DOI":"10.1007\/978-3-030-20301-6_17","volume-title":"Breast cancer metastasis drug resist [internet]","author":"B Bao","year":"2019","unstructured":"Bao B, Prasad AS. Targeting CSC in a most aggressive subtype of breast cancer TNBC. In: Ahmad A, editor. Breast cancer metastasis drug resist [internet]. Cham: Springer International Publishing; 2019. p.311\u201334. 2026 Mar 11. https:\/\/doi.org\/10.1007\/978-3-030-20301-6_17."},{"key":"8178_CR4","doi-asserted-by":"publisher","unstructured":"Emens LA, Adams S, Cimino-Mathews A, Disis ML, Gatti-Mays ME, Ho AY, et al. Society for immunotherapy of cancer (SITC) clinical practice guideline on immunotherapy for the treatment of breast cancer. J Immunother Cancer. 2021;9(8):e002597. https:\/\/doi.org\/10.1136\/jitc-2021-002597.","DOI":"10.1136\/jitc-2021-002597"},{"issue":"11","key":"8178_CR5","doi-asserted-by":"publisher","first-page":"991","DOI":"10.1038\/ni1102-991","volume":"3","author":"GP Dunn","year":"2002","unstructured":"Dunn GP, Bruce AT, Ikeda H, Old LJ, Schreiber RD. Cancer immunoediting: from immunosurveillance to tumor escape. Nat Immunol. 2002;3(11):991\u201398. https:\/\/doi.org\/10.1038\/ni1102-991.","journal-title":"Nat Immunol"},{"issue":"4","key":"8178_CR6","doi-asserted-by":"publisher","first-page":"250","DOI":"10.1016\/j.it.2015.02.003","volume":"36","author":"S-R Woo","year":"2015","unstructured":"Woo S-R, Corrales L, Gajewski TF. The STING pathway and the T cell-inflamed tumor microenvironment. Trends Immunol. 2015;36(4):250\u201356. https:\/\/doi.org\/10.1016\/j.it.2015.02.003.","journal-title":"Trends Immunol"},{"issue":"4","key":"8178_CR7","doi-asserted-by":"publisher","first-page":"361","DOI":"10.1158\/2326-6066.CIR-13-0127","volume":"2","author":"EA Mittendorf","year":"2014","unstructured":"Mittendorf EA, Philips AV, Meric-Bernstam F, Qiao N, Wu Y, Harrington S, et al. PD-L1 expression in triple-negative breast cancer. Cancer Immunol Res. 2014;2(4):361\u201370. https:\/\/doi.org\/10.1158\/2326-6066.CIR-13-0127.","journal-title":"Cancer Immunol Res"},{"issue":"2","key":"8178_CR8","doi-asserted-by":"publisher","first-page":"537","DOI":"10.1007\/s10555-021-09972-4","volume":"40","author":"AL Heeke","year":"2021","unstructured":"Heeke AL, Tan AR. Checkpoint inhibitor therapy for metastatic triple-negative breast cancer. Cancer Metastasis Rev. 2021;40(2):537\u201347. https:\/\/doi.org\/10.1007\/s10555-021-09972-4.","journal-title":"Cancer Metastasis Rev"},{"issue":"1\u20132","key":"8178_CR9","doi-asserted-by":"publisher","first-page":"334","DOI":"10.1016\/j.cell.2018.11.010","volume":"176","author":"J Wang","year":"2019","unstructured":"Wang J, Sanmamed MF, Datar I, Su TT, Ji L, Sun J, et al. Fibrinogen-like protein 1 is a Major immune inhibitory ligand of LAG-3. Cell. 2019;176(1\u20132):334\u201347.e12. https:\/\/doi.org\/10.1016\/j.cell.2018.11.010.","journal-title":"Cell"},{"key":"8178_CR10","doi-asserted-by":"publisher","first-page":"1649078","DOI":"10.3389\/fimmu.2025.1649078","volume":"16","author":"X Ou","year":"2025","unstructured":"Ou X, Yin J, Shi F, Zhao Y, Zhou Q, Yuan K, et al. CD155-TIGIT\/CD96\/CD226 immune checkpoint axis interacting with tumor-infiltrating lymphocytes to exhibit diverse prognostic effects on breast cancer: a cohort study. Front Immunol. 2025;16:1649078. https:\/\/doi.org\/10.3389\/fimmu.2025.1649078.","journal-title":"Front Immunol"},{"issue":"1","key":"8178_CR11","doi-asserted-by":"publisher","first-page":"16878","DOI":"10.1038\/s41598-017-17204-5","volume":"7","author":"P Bankhead","year":"2017","unstructured":"Bankhead P, Loughrey MB, Fern\u00e1ndez JA, Dombrowski Y, McArt DG, Dunne PD, et al. QuPath: open source software for digital pathology image analysis. Sci Rep. 2017;7(1):16878. https:\/\/doi.org\/10.1038\/s41598-017-17204-5.","journal-title":"Sci Rep"},{"issue":"8","key":"8178_CR12","doi-asserted-by":"publisher","first-page":"2255","DOI":"10.1002\/1521-4141(200208)32:8<2255::AID-IMMU2255>3.0.CO;2-A","volume":"32","author":"CJ Workman","year":"2002","unstructured":"Workman CJ, Rice DS, Dugger KJ, Kurschner C, Vignali DAA. Phenotypic analysis of the murine CD4-related glycoprotein, CD223 (LAG-3). Eur J Immunol. 2002;32(8):2255. https:\/\/doi.org\/10.1002\/1521-4141(200208)32:8%3C2255::AID-IMMU2255%3E3.0.CO;2-A.","journal-title":"Eur J Immunol"},{"issue":"5","key":"8178_CR13","doi-asserted-by":"publisher","first-page":"1177","DOI":"10.1016\/j.cell.2019.10.029","volume":"179","author":"S Jiao","year":"2019","unstructured":"Jiao S, Subudhi SK, Aparicio A, Ge Z, Guan B, Miura Y, et al. Differences in tumor microenvironment dictate T Helper lineage polarization and response to immune checkpoint therapy. Cell. 2019;179(5):1177\u201390.e13. https:\/\/doi.org\/10.1016\/j.cell.2019.10.029.","journal-title":"Cell"},{"issue":"8","key":"8178_CR14","doi-asserted-by":"publisher","first-page":"1856","DOI":"10.1158\/1078-0432.CCR-15-1849","volume":"22","author":"HM Zarour","year":"2016","unstructured":"Zarour HM. Reversing T-cell dysfunction and Exhaustion in cancer. Clin Cancer Res. 2016;22(8):1856\u201364. https:\/\/doi.org\/10.1158\/1078-0432.CCR-15-1849.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8178_CR15","doi-asserted-by":"publisher","first-page":"27","DOI":"10.1186\/1746-1596-7-27","volume":"7","author":"A Laurinavicius","year":"2012","unstructured":"Laurinavicius A, Laurinaviciene A, Ostapenko V, Dasevicius D, Jarmalaite S, Lazutka J. Immunohistochemistry profiles of breast ductal carcinoma: factor analysis of digital image analysis data. Diagn Pathol. 2012;7(1):27. https:\/\/doi.org\/10.1186\/1746-1596-7-27.","journal-title":"Diagn Pathol"},{"key":"8178_CR16","doi-asserted-by":"publisher","unstructured":"Verdicchio M, Brancato V, Cavaliere C, Isgr\u00f2 F, Salvatore M, Aiello M. A pathomic approach for tumor-infiltrating lymphocytes classification on breast cancer digital pathology images. Heliyon. 2023;9(3):e14371. https:\/\/doi.org\/10.1016\/j.heliyon.2023.e14371.","DOI":"10.1016\/j.heliyon.2023.e14371"},{"issue":"1","key":"8178_CR17","doi-asserted-by":"publisher","first-page":"604","DOI":"10.1186\/s40001-023-01583-9","volume":"28","author":"J Peng","year":"2023","unstructured":"Peng J, Du Z, Sun Y, Zhou Z. A combined analysis of multi-omics data reveals the prognostic values and immunotherapy response of LAG3 in human cancers. Eur J Med Res. 2023;28(1):604. https:\/\/doi.org\/10.1186\/s40001-023-01583-9.","journal-title":"Eur J Med Res"},{"issue":"1","key":"8178_CR18","doi-asserted-by":"publisher","first-page":"1756116","DOI":"10.1080\/2162402X.2020.1756116","volume":"9","author":"A Panda","year":"2020","unstructured":"Panda A, Rosenfeld JA, Singer EA, Bhanot G, Ganesan S. Genomic and immunologic correlates of LAG-3 expression in cancer. OncoImmunology. 2020;9(1):1756116. https:\/\/doi.org\/10.1080\/2162402X.2020.1756116.","journal-title":"OncoImmunology"},{"issue":"1","key":"8178_CR19","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12967-020-02469-8","volume":"18","author":"M Guo","year":"2020","unstructured":"Guo M, Yuan F, Qi F, Sun J, Rao Q, Zhao Z, et al. Expression and clinical significance of LAG-3, FGL1, PD-L1 and CD8+T cells in hepatocellular carcinoma using multiplex quantitative analysis. J Transl Med. 2020;18(1):306. https:\/\/doi.org\/10.1186\/s12967-020-02469-8.","journal-title":"J Transl Med"},{"issue":"17","key":"8178_CR20","doi-asserted-by":"publisher","first-page":"7875","DOI":"10.1073\/pnas.1003345107","volume":"107","author":"J Matsuzaki","year":"2010","unstructured":"Matsuzaki J, Gnjatic S, Mhawech-Fauceglia P, Beck A, Miller A, Tsuji T, et al. Tumor-infiltrating NY-ESO-1\u2013specific CD8 + T cells are negatively regulated by LAG-3 and PD-1 in human ovarian cancer. Proc Natl Acad Sci USA. 2010;107(17):7875\u201380. https:\/\/doi.org\/10.1073\/pnas.1003345107.","journal-title":"Proc Natl Acad Sci USA"},{"issue":"12","key":"8178_CR21","doi-asserted-by":"publisher","first-page":"2977","DOI":"10.1093\/annonc\/mdx557","volume":"28","author":"S Burugu","year":"2017","unstructured":"Burugu S, Gao D, Leung S, Chia SK, Nielsen TO. LAG-3+ tumor infiltrating lymphocytes in breast cancer: clinical correlates and association with PD-1\/PD-L1+ tumors. Ann Oncol. 2017;28(12):2977\u201384. https:\/\/doi.org\/10.1093\/annonc\/mdx557.","journal-title":"Ann Oncol"},{"issue":"6","key":"8178_CR22","doi-asserted-by":"publisher","first-page":"2350","DOI":"10.1172\/JCI46102","volume":"121","author":"L Baitsch","year":"2011","unstructured":"Baitsch L, Baumgaertner P, Dev\u00eavre E, Raghav SK, Legat A, Barba L, et al. Exhaustion of tumor-specific CD8+ T cells in metastases from melanoma patients. J. Clin. Invest. 2011;121(6):2350\u201360. https:\/\/doi.org\/10.1172\/JCI46102.","journal-title":"J. Clin. Invest"},{"issue":"13","key":"8178_CR23","doi-asserted-by":"publisher","first-page":"3031","DOI":"10.1158\/1078-0432.CCR-14-2926","volume":"21","author":"NA Giraldo","year":"2015","unstructured":"Giraldo NA, Becht E, Pag\u00e8s F, Skliris G, Verkarre V, Vano Y, et al. Orchestration and prognostic significance of immune checkpoints in the microenvironment of primary and metastatic renal cell cancer. Clin Cancer Res. 2015;21(13):3031\u201340. https:\/\/doi.org\/10.1158\/1078-0432.CCR-14-2926.","journal-title":"Clin Cancer Res"},{"issue":"1","key":"8178_CR24","doi-asserted-by":"publisher","first-page":"306","DOI":"10.1186\/s12935-023-03157-5","volume":"23","author":"R Li","year":"2023","unstructured":"Li R, Qiu J, Zhang Z, Qu C, Tang Z, Yu W, et al. Prognostic significance of lymphocyte-activation gene 3 (LAG3) in patients with solid tumors: a systematic review, meta-analysis and pan-cancer analysis. Cancer Cell Int. 2023;23(1):306. https:\/\/doi.org\/10.1186\/s12935-023-03157-5.","journal-title":"Cancer Cell Int"}],"container-title":["Journal of Translational Medicine"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/article\/10.1186\/s12967-026-08178-y","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1186\/s12967-026-08178-y.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,6,14]],"date-time":"2026-06-14T22:41:02Z","timestamp":1781476862000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1186\/s12967-026-08178-y"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,4,27]]},"references-count":24,"journal-issue":{"issue":"1","published-online":{"date-parts":[[2026,12]]}},"alternative-id":["8178"],"URL":"https:\/\/doi.org\/10.1186\/s12967-026-08178-y","relation":{},"ISSN":["1479-5876"],"issn-type":[{"value":"1479-5876","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,4,27]]},"assertion":[{"value":"17 March 2026","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"8 April 2026","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"27 April 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"The authors declare that they have no competing interests","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Competing interests"}}],"article-number":"767"}}